Innoviva, Inc. (INVA)
23.39
-0.25
(-1.06%)
USD |
NASDAQ |
Feb 20, 16:00
23.38
0.00 (0.00%)
After-Hours: 20:00
Innoviva SG&A Expense (Quarterly) : 27.29M for Sept. 30, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Merck & Co., Inc. | 2.898B |
| Nektar Therapeutics | 16.07M |
| Regeneron Pharmaceuticals, Inc. | 775.00M |
| Oramed Pharmaceuticals, Inc. | 1.274M |
| Theravance Biopharma, Inc. | 18.33M |